European Union - English - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastic agents - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Canada - English - Health Canada

incyte corporation - pemigatinib - tablet - 4.5mg - pemigatinib 4.5mg - antineoplastic agents

Canada - English - Health Canada

incyte corporation - pemigatinib - tablet - 9mg - pemigatinib 9mg - antineoplastic agents

Canada - English - Health Canada

incyte corporation - pemigatinib - tablet - 13.5mg - pemigatinib 13.5mg - antineoplastic agents

Israel - English - Ministry of Health

medison pharma ltd - pemigatinib - tablets - pemigatinib 13.5 mg - pemigatinib - pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as determined by a validated test.

Israel - English - Ministry of Health

medison pharma ltd - pemigatinib - tablets - pemigatinib 4.5 mg - pemigatinib - pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as determined by a validated test.

Israel - English - Ministry of Health

medison pharma ltd - pemigatinib - tablets - pemigatinib 9 mg - pemigatinib - pemazyre is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as determined by a validated test.